Safe Formulations Pvt Ltd registered with Pharmexcil in 2008 as a small-scale manufacturer. Pharmexcil has asked the company to furnish the details of licensees, procurers, manufacturing license copies and product permissions of the drug by 27 April, failing which its registration will be suspended, said Pharmexcil director general Uday Bhasker.
The global takotsubo syndrome therapeutics market is predicted to exceed an impressive valuation of US$ 2.85 Billion in 2033, with a compound annual growth rate (CAGR) of 6.1% estimated from 2023 to 2033. In both industrialized and developing economies, cardiovascular diseases are the leading cause of death. The ris.